- Sarepta Therapeutics ( NASDAQ: SRPT ) is up 16% in after-hours trading after it was informed by the US FDA that it would not need to hold an advisory committee for its Biologics License Application for SRP-9001 for Duchenne muscular dystrophy.
- The candidate, also known as delandistrogene moxeparvovec, has an FDA action date of May 29 . It is under development with Roche ( OTCQX:RHHBY ).
- Read why Seeking Alpha contributor Terry Chrisomalis recently reiterated his strong buy rating .
For further details see:
Sarepta up 16% after no FDA advisory meeting for Duchenne therapy